molecularneuroscience

  • New Trial Data Is Strongest Yet for Any Experimental Alzheimer’s Drug

    New Trial Data Is Strongest Yet for Any Experimental Alzheimer’s Drug

    New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomised, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo, with nearly half of those on the drug experiencing no decline…